Harrington Discovery Institute Announces New Fund to Advance Breakthrough Discoveries into Novel Treatments
The Advent-Harrington Impact Fund contributes to $215 million close of Advent Life Sciences’ funds focused on areas of high unmet medical need
Newswise — CLEVELAND—The transatlantic, not-for-profit medical accelerator, Harrington Discovery Institute (HDI) at University Hospitals, has collaborated with leading venture investor, Advent Life Sciences (‘Advent’) in the launch of the Advent-Harrington Impact Fund.
Advent’s new impact fund, structured alongside Advent Life Sciences Fund III, brings a total of $215 million to advance breakthrough discoveries into novel treatments for the benefit of patients and society.
Advent-Harrington Impact Fund, a market rate investment fund, breaks new ground through a partnership with a novel philanthropic vehicle at Morgan Stanley Wealth Management (MS GIFT Cures powered by HDI). Profits from Advent-Harrington Impact Fund are shared with HDI to create the means to